122 related articles for article (PubMed ID: 21083653)
1. Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients.
Guglielmelli T; Petrucci MT; Saglio G; Palumbo A
Br J Haematol; 2011 Jan; 152(1):108-10. PubMed ID: 21083653
[No Abstract] [Full Text] [Related]
2. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients.
Guglielmelli T; Bringhen S; Rrodhe S; Gay F; Cavallo F; Berruti A; Montefusco V; Piro E; Benevolo G; Petrucci MT; Caravita T; Offidani M; Corradini P; Boccadoro M; Saglio G; Palumbo A
Eur J Cancer; 2011 Apr; 47(6):814-8. PubMed ID: 21334196
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Kukreti V; Masih-Khan E; Young T; Chu CM; Jiang H; Trudel S; Chen C; Jimenez-Zepeda V; Reece DE
Am J Hematol; 2013 Apr; 88(4):337-8. PubMed ID: 23494911
[No Abstract] [Full Text] [Related]
4. Lenalidomide: an update on evidence from clinical trials.
Dimopoulos MA; Terpos E
Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
[TBL] [Abstract][Full Text] [Related]
5. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients.
Goldschmidt H; Sonneveld P; Cremer FW; van der Holt B; Westveer P; Breitkreutz I; Benner A; Glasmacher A; Schmidt-Wolf IG; Martin H; Hoelzer D; Ho AD; Lokhorst HM; ;
Ann Hematol; 2003 Oct; 82(10):654-9. PubMed ID: 12845480
[No Abstract] [Full Text] [Related]
6. Novel agents for relapsed and/or refractory multiple myeloma.
Thomas SK; Richards TA; Weber DM
Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168
[TBL] [Abstract][Full Text] [Related]
7. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Richardson P
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S9-15. PubMed ID: 16344100
[TBL] [Abstract][Full Text] [Related]
8. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in multiple myeloma: current role and future directions.
Zeldis JB; Knight RD; Jacques C; Tozer A; Bizzari JP
Expert Opin Pharmacother; 2010 Apr; 11(5):829-42. PubMed ID: 20210686
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma.
Kapoor P; Kumar S; Mandrekar SJ; Laumann KM; Dispenzieri A; Lacy MQ; Dingli D; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV; Witzig TE
Leukemia; 2011 Jul; 25(7):1195-7. PubMed ID: 21468037
[No Abstract] [Full Text] [Related]
12. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Dimopoulos M; Spencer A; Attal M; Prince HM; Harousseau JL; Dmoszynska A; San Miguel J; Hellmann A; Facon T; Foà R; Corso A; Masliak Z; Olesnyckyj M; Yu Z; Patin J; Zeldis JB; Knight RD;
N Engl J Med; 2007 Nov; 357(21):2123-32. PubMed ID: 18032762
[TBL] [Abstract][Full Text] [Related]
13. Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Morris TC; Kettle PJ; Drake M; Jones FC; Hull DR; Boyd K; Morrison A; Clarke P; O'Reilly P; Quinn J
Br J Haematol; 2008 Nov; 143(3):349-54. PubMed ID: 18759764
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
Caravita T; Siniscalchi A; Tendas A; Cupelli L; Ales M; Perrotti A; Niscola P; de Fabritiis P
Ann Hematol; 2011 Jan; 90(1):115-6. PubMed ID: 20422414
[No Abstract] [Full Text] [Related]
15. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide and its role in the management of multiple myeloma.
Falco P; Cavallo F; Larocca A; Liberati AM; Musto P; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2008 Jun; 8(6):865-74. PubMed ID: 18533796
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients.
Morgan GJ; Schey SA; Wu P; Srikanth M; Phekoo KJ; Jenner M; Davies FE
Br J Haematol; 2007 May; 137(3):268-9. PubMed ID: 17408469
[No Abstract] [Full Text] [Related]
18. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
20. Ultra low dose thalidomide in elderly patients with myeloma.
Bowcock SJ; Minchom A; Yates LR; Ryali MM
Br J Haematol; 2008 Apr; 141(1):120-2. PubMed ID: 18279458
[No Abstract] [Full Text] [Related]
[Next] [New Search]
